Search Filters

Search Results

Found 2 results

510(k) Data Aggregation

    K Number
    K141874
    Device Name
    URISCAN OPTIMA
    Date Cleared
    2015-05-28

    (321 days)

    Product Code
    Regulation Number
    862.2900
    Reference & Predicate Devices
    Predicate For
    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The URISCAN Optima urine chemistry test system consists of URiSCAN Optima Urine analyzer and URISCAN 2ACR Urine strips. The intended use of the URiSCAN Optima Urine analyzer is to read the color change on the test pads found on the URiSCAN 2ACR Urine strips and to display and print the results.

    The intended use of the URiSCAN 2ACR Urine strips is for the in vitro semi quantitative measurement of the following parameters;

    Albumin Creatinine ACR (Albumin Creatinine Ratio)

    These measurements are useful in the evaluation of renal, urinary and metabolic disorders. URiSCAN Optima urine chemistry test system is intended for prescription use only, in clinical laboratory and in point-of-care setting.

    Device Description

    URiSCAN Optima - the semi-quantitative urine analyzer is used with the aim of helping examine patients in a professional setting through early detection of disease before they get a thorough checkup, by using chemical components contained in urine; and it is a device to measure the amounts of components in urine, including albumin, creatinine and ACR (albumin creatinine ratio). The results appear on a liquid crystal display and can be printed on the analyzer's internal printer and transferred to a host computer, if desired.

    AI/ML Overview

    Here's a breakdown of the acceptance criteria and study information for the URiSCAN Optima Urine analyzer and URiSCAN 2ACR Urine strips, extracted from the provided text:


    Acceptance Criteria and Device Performance

    ParameterAcceptance Criteria (Target/Threshold)Reported Device Performance (Exact agreement with predicate device)
    MicroalbuminNot explicitly stated as a single numeric threshold for exact agreement, but implied to be high agreement with predicate.95.7% (Overall) 100.0% (Positive Agreement) 100.0% (Negative Agreement)
    CreatinineNot explicitly stated as a single numeric threshold for exact agreement, but implied to be high agreement with predicate.96.6% (Overall)
    ACRNot explicitly stated as a single numeric threshold for exact agreement, but implied to be high agreement with predicate.98.0% (Overall) 97.8% (Positive Agreement) 98.3% (Negative Agreement)

    Note on "Acceptance Criteria": The document does not explicitly state pre-defined numeric acceptance criteria for the outcome percentages of the comparison studies (e.g., "must be >95% exact agreement"). Instead, the comparison study results are the performance claims being used to demonstrate substantial equivalence. However, for precision, there are implicit criteria for "Level 1 - Negative Control" and "Level 2 - Positive Control" for Microalbumin and Creatinine in the precision tests.

    Test ItemLevel 1 - Negative ControlLevel 2 - Positive Control
    Microalbumin≤10mg/L80-≥150mg/L
    Creatinine10-50mg/dL100 - ≥300mg/dL

    For precision, the reported performance was 100% for all sites (A, B, C) and both levels for both Microalbumin and Creatinine.


    Study Information

    1. Sample size used for the test set and the data provenance:

      • Sample Size: 351 random urine specimens.
      • Data Provenance: Fresh urine specimens collected in a clean, dry container at three different Point-of-Care (POC) sites (157 samples at the first, 99 at the second, and 95 at the third). This indicates prospective collection at multiple sites. The country of origin is not explicitly stated, but given the manufacturer is based in Korea and the submission is to the FDA, it could be either U.S. or international data.
    2. Number of experts used to establish the ground truth for the test set and the qualifications of those experts:

      • Does not apply. The ground truth in this comparison study was established by another device (predicate device: Clinitek Status with Clinitek Microalbumin 2 reagent strips), not human experts.
    3. Adjudication method for the test set:

      • Does not apply. Ground truth was established by a predicate device, so no human adjudication was performed.
    4. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:

      • No. This was a method comparison study comparing the performance of two automated devices (URISCAN Optima vs. Clinitek Status) on urine chemistry analysis. It was not an MRMC study and did not involve human readers or AI assistance in that context.
    5. If a standalone (i.e., algorithm only without human-in-the-loop performance) was done:

      • Yes. The method comparison study directly evaluated the performance of the URiSCAN Optima Urine analyzer (an algorithm-driven device) against a predicate device. This is a standalone performance assessment of the device's ability to read and interpret the urine strips.
    6. The type of ground truth used (expert consensus, pathology, outcomes data, etc.):

      • The ground truth was established by comparison with a legally marketed predicate device: "Clinitek Status with Clinitek Microalbumin 2 reagent strips".
    7. The sample size for the training set:

      • The document does not provide details on the sample size for a "training set." This type of device (a urine chemistry analyzer) typically operates based on calibrated spectrophotometric readings of test pads rather than machine learning algorithms trained on large datasets in the way an AI-driven imaging diagnostic device would. Calibration and control samples are used, but a "training set" in the context of deep learning is not applicable here.
    8. How the ground truth for the training set was established:

      • Does not apply in the context of a machine learning training set. For calibration and control solutions, the "ground truth" (target values) were established through an internal procedure using commercially available stock of albumin and creatinine in buffered solutions, and re-checked using a commercial calibrator set.
    Ask a Question

    Ask a specific question about this device

    K Number
    K050801
    Manufacturer
    Date Cleared
    2005-04-20

    (21 days)

    Product Code
    Regulation Number
    862.1340
    Reference & Predicate Devices
    N/A
    Predicate For
    N/A
    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The UriScan Optima II Urine Analyzer is an automated system for use with UriScan Strip. For routine urinalysis through the analysis of blood, bilirubin, urobilinogen, ketones, protein, nitrite, glucose, pH, specific gravity, and leukocytes, as well as the determination of color.

    Device Description

    Not Found

    AI/ML Overview

    The provided text is a 510(k) premarket notification letter from the FDA for a device called "UriScan Optima II Urine Analyzer." It broadly approves the device for marketing and mentions its intended use. However, it does not contain any information regarding acceptance criteria, study details, or performance metrics that would allow me to answer your specific questions.

    The document states: "We have reviewed your Section 510(k) premarket notification of intent to market the device we have reviewed your betermined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices..." This indicates that the device was deemed substantially equivalent to existing devices, but the specific studies and acceptance criteria that led to this determination are not included in the provided text.

    Therefore, I cannot provide the requested information based on the given input.

    Ask a Question

    Ask a specific question about this device

    Page 1 of 1